Large Israeli study shows Pfizer's vaccine cuts symptomatic COVID-19 by 94 percent


Israel has now fully vaccinated 28 percent of its population against COVID-19 and administered the first dose to 42 percent of its nine million inhabitants, and its data is very promising. Clalit, the largest of Israel's four health-care providers, reported Sunday that the Pfizer-BioNTech vaccine has resulted in a 94 percent drop in symptomatic COVID-19 infections among those who have gotten both doses and a 92 percent decline in severe illness.
Clalit compared 600,000 Israelis who have been fully vaccinated against an equal number who have not, pairing vaccinated people and non-vaccinated people with a similar age and health profile. The majority of people studied were age 16 to 59, but 170,000 of the 600,000 Israelis were 60 or older. "It is now unequivocal that Pfizer's vaccine against the coronavirus is incredibly effective in real life one week after the second dose, just as was found in the clinical study," Ran Balicer, Clalit's chief innovation officer and one of the study's authors, said in a statement Sunday. He said the vaccine is even more effective two weeks after the second shot.
Israel plans to inoculate most of its population by March, and in return for its early access to the Pfizer vaccine, the country agreed to share its data on vaccine safety, effectiveness, and side effects, The Wall Street Journal reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Overall, COVID-19 cases have dropped by 41 percent in Israel while hospitalizations have dropped by a third, public health experts Ezekiel Emanuel, Céline Gounder, Michael Osterholm, Luciana Borio, Atul Gawande, and Rick Bright write in a USA Today op-ed. "All seven COVID-19 vaccines that have completed large efficacy trials" appear "to be 100 percent effective for serious complications" and death, they added, so "our advice is simple: Take whatever vaccine is offered to you. Right now, all of the vaccines are the 'best.'"
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Today's political cartoons - April 26, 2025
Cartoons Saturday's cartoons - road to victory, biggest guns, and more
By The Week US
-
5 holier-than-thou cartoons about the Pope's passing
Cartoons Artists take on a new ride, an old hat, and more
By The Week US
-
Creamy kale slaw with hazelnuts recipe
The Week Recommends This slaw with a 'cracking texture' makes the perfect side that will elevate any meal
By The Week Staff
-
Markets notch worst quarter in years as new tariffs loom
Speed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
By Peter Weber, The Week US
-
Tesla Cybertrucks recalled over dislodging panels
Speed Read Almost every Cybertruck in the US has been recalled over a stainless steel panel that could fall off
By Justin Klawans, The Week US
-
Crafting emporium Joann is going out of business
Speed Read The 82-year-old fabric and crafts store will be closing all 800 of its stores
By Peter Weber, The Week US
-
Trump's China tariffs start after Canada, Mexico pauses
Speed Read The president paused his tariffs on America's closest neighbors after speaking to their leaders, but his import tax on Chinese goods has taken effect
By Peter Weber, The Week US
-
Chinese AI chatbot's rise slams US tech stocks
Speed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
By Peter Weber, The Week US
-
US port strike averted with tentative labor deal
Speed Read The strike could have shut down major ports from Texas to Maine
By Peter Weber, The Week US
-
Biden expected to block Japanese bid for US Steel
Speed Read The president is blocking the $14 billion acquisition of U.S. Steel by Japan's Nippon Steel, citing national security concerns
By Peter Weber, The Week US
-
Judges block $25B Kroger-Albertsons merger
Speed Read The proposed merger between the supermarket giants was stalled when judges overseeing two separate cases blocked the deal
By Peter Weber, The Week US